John Wiley & Sons Animal Models for the Development of Cancer Immunotherapy Cover This book provides a detailed overview of different preclinical model systems for development of nov.. Product #: 978-1-119-53528-7 Regular price: $151.40 $151.40 Auf Lager

Animal Models for the Development of Cancer Immunotherapy

Tan, Seng-Lai (Herausgeber)

Cover

1. Auflage August 2022
320 Seiten, Hardcover
Wiley & Sons Ltd

ISBN: 978-1-119-53528-7
John Wiley & Sons

Kurzbeschreibung

This book provides a detailed overview of different preclinical model systems for development of novel cancer immunotherapies while highlighting how key aspects of individual models translate into clinical findings. Covering the introduction, development, and therapeutic applications of animal models for cancer immunotherapy, this comprehensive volume helps pharmacologists identify suitable animal models, design pharmacological or translational studies, and advance their mechanistic understanding of therapeutic agents, and increase the possibility of success for novel immunotherapies in clinical settings. Chapters written by prominent leaders in the field address specific models that evaluate immuno-oncology drugs are supported by in-depth case studies and extensive references throughout.

Jetzt kaufen

Preis: 162,00 €

Preis inkl. MwSt, zzgl. Versand

Weitere Versionen

epubmobi

Animal Models for the Development of Cancer Immunotherapy

Provides readers with a clear understanding of the value and challenges of using common and emerging preclinical models in cancer immunotherapy research and development.

Animal models are essential tools for studying a range of issues in preclinical and clinical research on therapies targeting cancerous tumors. As clinical trials of advances in cancer immunotherapy are predicted to outpace preclinical research in the near future, there remains an urgent need to develop better animal models for preclinical evaluation of novel modulators. Animal Models for the Development of Cancer Immunotherapy provides a detailed overview of different preclinical model systems for development of novel cancer immunotherapies while highlighting how key aspects of individual models translate into clinical findings.

Covering the introduction, development, and therapeutic applications of animal models for cancer immunotherapy, this comprehensive volume helps pharmacologists identify suitable animal models, design pharmacological or translational studies, and advance their mechanistic understanding of therapeutic agents, and increase the possibility of success for novel immunotherapies in clinical settings. Chapters written by prominent leaders in the field address specific models that evaluate immuno-oncology drugs are supported by in-depth case studies and extensive references throughout.
* Emphasizes the importance of modeling tumor metastasis in preclinical models for efficient translation of findings into the clinic
* Explores recently discovered mechanisms of resistance and their preclinical modeling
* Highlights the unique characteristics and features of autologous and allogeneic approaches for humanization of mouse models
* Reviews development of bone marrow-liver-thymus (BLT) immune humanized mice and emerging alternative models such as genetically engineered mouse models (GEMM)
* Discusses alternative animal models for cancer research such as severe combined immunodeficiency (SCID) pigs

Animal Models for the Development of Cancer Immunotherapy is an essential resource for scientists and researchers in the pharmaceutical and biotechnology industries, medicinal chemists and biochemists, cell and molecular biologists, pharmacologists, immunologists, and clinicians.

Table of Content


Introduction

Kannan Karupiah, Mithun Khattar



1. Transplantable Syngeneic Tumor Models

Richard Woessner, Simon Dovedi, Robert Wilkinson


2. Genetically Engineered Mouse Models (GEMM) in Cancer Immunotherapy R&D

Zhao Chen


3. Mouse Tumor Homografts Recapitulate Human Molecular Pathogenesis

Rajendra Kumari, Davy Ouyang, Henry Li.



4. Modeling Resistance to Immune Checkpoint Blockade

Michael Quigley, Matthew J. Meyer and Kanstantsin Katlinski


5. Orthotopic Mouse Models of Colorectal Cancer and Imaging Techniques

Ce Yuan, Xianda Zhao, Dechen Wangmo, Duha Alshareef, Subbaya Subramanian



6. Preclinical Osteoimmuno-oncology Models to Study Effects of Immunotherapies on Bone Metastasis

Tiina E. Kähkönen, Jussi M. Halleen, Jenni Bernoulli



7.Humanized mouse models for cancer immunotherapy: a focus on human PBMC and HSPC reconstitution

Zhuo Li, Xiao Yang, Xiaomin Song



8. Bone Marrow-Liver-Thymus (BLT) Humanized Mice as a Tool to Assess Checkpoint Inhibitor Adverse Events

Kenrick M. Semple, Alan D. Knapton and Kristina E. Howard


9. Development of Swine Models for Cancer Research: SCID Pigs and Other Emerging Pig Models

Adeline N Boettcher and Christopher K Tuggle


Index
Seng-Lai Tan, PhD, is Chief Scientific Officer at Immunitas Therapeutics. He has more than 20 years of drug discovery and development experience in both small and large molecule therapeutic modalities, including multi-specific antibodies and stapled peptides. He is former Head of Immunology at Marengo (Elstar) Therapeutics and Forma Therapeutics, and has held leadership positions at EMD Serono Research & Development Institute and Roche.

S.-L. Tan, Elstar Therapeutics, Cambridge, USA